- Conditions
- Narcolepsy
- Interventions
- SUVN-G3031, Placebo
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
- Interventions
- CEP-10953 (Armodafinil)
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Narcolepsy Type 1, Narcolepsy Type 2
- Interventions
- cleminorexton, Placebo
- Drug
- Lead sponsor
- Centessa Pharmaceuticals (UK) Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Huntersville, North Carolina • Columbia, South Carolina
- Conditions
- Narcolepsy Type 2
- Interventions
- Placebo, TAK-861 2 mg, TAK-861 2 mg and 5 mg
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 18 more
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Somnolence, Sleep Disorder, Sleep Disturbance, Sleep Wake Disorders
- Interventions
- FT218
- Drug
- Lead sponsor
- Avadel
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Redwood City, California • Santa Ana, California + 24 more
- Conditions
- Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
- Interventions
- TAK-994, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 36
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more
- Conditions
- Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
- Interventions
- Modafinil, Amphetamine-Dextroamphetamine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
- Interventions
- AXS-12 (reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 47
- States / cities
- Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more
- Conditions
- Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
- Interventions
- mazindol extended release, Placebo
- Drug
- Lead sponsor
- NLS Pharmaceutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
- Interventions
- AXS-12 (reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
- Conditions
- Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
- Interventions
- TAK-861, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 11
- States / cities
- Redwood City, California • Brandon, Florida • Miami, Florida + 8 more
- Conditions
- Narcolepsy With Cataplexy
- Interventions
- Xyrem
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 17
- States / cities
- Long Beach, California • Orange, California • Redwood City, California + 14 more